Tildrakizumab efficacy,drug survival,and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) |
| |
| Authors: | Mark G. Lebwohl Craig L. Leonardi Nehal N. Mehta Alice B. Gottlieb Alan M. Mendelsohn Jeff Parno Stephen J. Rozzo M. Alan Menter |
| |
| Affiliation: | 1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York;2. Central Dermatology and Saint Louis University School of Medicine, St Louis, Missouri;3. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD;4. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York;5. Sun Pharmaceutical Industries, Inc, Princeton, New Jersey;6. Division of Dermatology, Baylor Scott & White, Dallas, Texas;7. Texas A&M College of Medicine, Dallas, Texas |
| |
| Abstract: | ![]()
|
| |
| Keywords: | clinical research dermatology efficacy interleukin 23 metabolic syndrome psoriasis safety tildrakizumab AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0055" }," $$" :[{" #name" :" text" ," _" :" adverse event BMI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0065" }," $$" :[{" #name" :" text" ," _" :" body mass index CV" },{" #name" :" keyword" ," $" :{" id" :" kwrd0075" }," $$" :[{" #name" :" text" ," _" :" cardiovascular CVD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0085" }," $$" :[{" #name" :" text" ," _" :" cardiovascular disease IL" },{" #name" :" keyword" ," $" :{" id" :" kwrd0095" }," $$" :[{" #name" :" text" ," _" :" interleukin MACE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0105" }," $$" :[{" #name" :" text" ," _" :" major adverse cardiovascular event MedDRA SOC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0115" }," $$" :[{" #name" :" text" ," _" :" Medical Dictionary for Regulatory Activities System Organ Class MetS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0125" }," $$" :[{" #name" :" text" ," _" :" metabolic syndrome NCEP ATP III" },{" #name" :" keyword" ," $" :{" id" :" kwrd0135" }," $$" :[{" #name" :" text" ," _" :" National Cholesterol Education Programme Adult Treatment Panel III PASI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0145" }," $$" :[{" #name" :" text" ," _" :" Psoriasis Area and Severity Index PY" },{" #name" :" keyword" ," $" :{" id" :" kwrd0155" }," $$" :[{" #name" :" text" ," _" :" patient-years SAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0165" }," $$" :[{" #name" :" text" ," _" :" serious adverse event TEAE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0175" }," $$" :[{" #name" :" text" ," _" :" treatment-emergent adverse event |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
